Liquid Biopsy as Surrogate to Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis towards Precision Medicine

Luchini, Claudio and Veronese, Nicola and Nottegar, Alessia and Cappelletti, Vera and Daidone, Maria and Smith, Lee and Parris, Christopher N. and Brosens, Lodewijk and Caruso, Maria G. and Cheng, Liang and Wolfgang, Christopher and Wood, Laura and Milella, Michele and Salvia, Roberto and Scarpa, Aldo (2019) Liquid Biopsy as Surrogate to Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis towards Precision Medicine. Cancers, 11 (8). p. 1152. ISSN 2072-6694

[img]
Preview
Text
Published Version
Available under the following license: Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview
[img] Text
Accepted Version
Restricted to Repository staff only
Available under the following license: Creative Commons Attribution Non-commercial No Derivatives.

Download (3MB) | Request a copy
Official URL: https://doi.org/10.3390/cancers11081152

Abstract

Liquid biopsy (LB) is a non-invasive approach representing a promising tool for new precision medicine strategies for cancer treatment. However, a comprehensive analysis of its reliability for pancreatic cancer (PC) is lacking. To this aim, we performed the first meta-analysis on this topic. We calculated the pooled sensitivity, specificity, positive (LR+) and negative (LR−) likelihood ratio, and diagnostic odds ratio (DOR). A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall accuracy. We finally assessed the concordance rate of all mutations detected by multi-genes panels. Fourteen eligible studies involving 369 patients were included. The overall pooled sensitivity and specificity were 0.70 and 0.86, respectively. The LR+ was 3.85, the LR- was 0.34 and DOR was 15.84. The SROC curve with AUC of 0.88 indicated a relatively high accuracy of LB for molecular characterization of PC. The concordance rate of all mutations detected by multi-genes panels was 31.9%. LB can serve as surrogate to tissue in molecular profiling of PC, because of its relatively high sensitivity, specificity and accuracy. It represents a unique opportunity to be further explored towards its introduction in clinical practice and for developing new precision medicine approaches against PC.

Item Type: Journal Article
Keywords: liquid biopsy, cfDNA, pancreatic cancer, precision medicine, circulating tumor cells (CTC)
Faculty: Faculty of Science & Engineering
Depositing User: Lee Smith
Date Deposited: 07 Aug 2019 14:11
Last Modified: 14 Nov 2019 16:07
URI: http://arro.anglia.ac.uk/id/eprint/704623

Actions (login required)

Edit Item Edit Item